Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees2
Next Earnings Date5/2/2019 (Estimated)
OptionableNot Optionable
Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions
What is Avenue Therapeutics' stock symbol?
Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."
How were Avenue Therapeutics' earnings last quarter?
Avenue Therapeutics Inc (NASDAQ:ATXI) announced its quarterly earnings results on Tuesday, August, 14th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.23. View Avenue Therapeutics' Earnings History.
When is Avenue Therapeutics' next earnings date?
What price target have analysts set for ATXI?
2 brokerages have issued twelve-month price targets for Avenue Therapeutics' shares. Their predictions range from $10.00 to $11.00. On average, they expect Avenue Therapeutics' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 89.2% from the stock's current price. View Analyst Price Targets for Avenue Therapeutics.
What is the consensus analysts' recommendation for Avenue Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avenue Therapeutics.
Has Avenue Therapeutics been receiving favorable news coverage?
Media stories about ATXI stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avenue Therapeutics earned a news impact score of 1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Avenue Therapeutics' key competitors?
Some companies that are related to Avenue Therapeutics include Athersys (ATHX), Mersana Therapeutics (MRSN), Spero Therapeutics (SPRO), Galectin Therapeutics (GALT), CELYAD SA/ADR (CYAD), Intec Pharma (NTEC), Adamas Pharmaceuticals (ADMS), Aldeyra Therapeutics (ALDX), Proteostasis Therapeutics (PTI), Arbutus Biopharma (ABUS), Axovant Sciences (AXGT), MEI Pharma (MEIP), LifeVantage (LFVN), Ardelyx (ARDX) and Paratek Pharmaceuticals (PRTK).
What other stocks do shareholders of Avenue Therapeutics own?
Who are Avenue Therapeutics' key executives?
Avenue Therapeutics' management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)
- Dr. Lucy Lu, Pres, CEO & Director (Age 44)
- Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)
- Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72)
When did Avenue Therapeutics IPO?
(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.
Who are Avenue Therapeutics' major shareholders?
Avenue Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (4.65%), National Asset Management Inc. (0.62%) and Northern Trust Corp (0.14%). Company insiders that own Avenue Therapeutics stock include Jeffrey Paley, Lindsay A Md Rosenwald and Neil Herskowitz. View Institutional Ownership Trends for Avenue Therapeutics.
Which institutional investors are buying Avenue Therapeutics stock?
ATXI stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Northern Trust Corp and National Asset Management Inc.. Company insiders that have bought Avenue Therapeutics stock in the last two years include Jeffrey Paley, Lindsay A Md Rosenwald and Neil Herskowitz. View Insider Buying and Selling for Avenue Therapeutics.
How do I buy shares of Avenue Therapeutics?
Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avenue Therapeutics' stock price today?
One share of ATXI stock can currently be purchased for approximately $5.55.
How big of a company is Avenue Therapeutics?
Avenue Therapeutics has a market capitalization of $59.21 million. The company earns $-21,550,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Avenue Therapeutics employs 2 workers across the globe.
What is Avenue Therapeutics' official website?
How can I contact Avenue Therapeutics?
Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)
MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
